ViroCarb
Platform & Pipeline

From Discovery to the Clinic

ViroCarb is advancing multiple preclinical delivery programs targeting unmet needs in antiviral treatments

THE PIPELINE • DEVELOPMENT PLAN

One Platform, Targeting Multiple Viruses

Transforming treatment of viral infections with unmet need

ProgramRoute Adm.DiscoveryTarget & pathway validationLead candidate selectionPreclinical proof of conceptGLP safety & tox studiesPhase 1Phase 2Phase 3
GPS543 Respiratory VirusesOral
Phase 1b (flu and COVID-19 patients), target completion, ~24 months, planned Phase 2/3 expansion into additional indications.
GPS543 InfluenzaNasal
Influenza A human challenge trials (CHIM) in the Netherlands (CHDR/INFECTA) target completion in ~18 months, with expansion to other respiratory viruses.
Viral eye infections AdenovirusTopical Eye Formulation
Advancing a topical broad-spectrum lead candidate for major viral Eye infections through strategic pharma partnership.
Multiple Viruses & ConditionsOral
In vitro and in vivo evaluation of our compound library against different viral infections with unmet clinical needs.
Oral Delivery

Oral GPS543

Oral GPS543 — Phase II/III multiple viruses: Coronavirus, Influenza, Adenovirus, Ebola, HIV

A single Phase 1 safety trial unlocks the potential to treat multiple distinct viral indications

  • Our goal is to complete safety studies with proof of principle of efficacy against influenza and coronavirus.

  • Findings will support testing against multiple viruses in phase II/III clinical trials.

  • Faster and cost-effective process, which avoids the need to separate safety trials for each different viral infection.

Market Insights

  • ▸

    $45B 2026 → ~$55B 2030 coronavirus + influenza [Cognitive-Market-Research, 2026]

  • ▸

    Opportunity to expand into broader viral infections via a single Phase 1 program

Intranasal Delivery

Intranasal GPS543

Intranasal GPS543 — respiratory delivery illustration showing lungs and nasal spray administration

Frontline Respiratory Defense

  • Current treatments for respiratory infections are limited to high-risk individuals and are affected by drug resistance.

  • ViroCarb plans to deliver intranasally GPS543 to directly target these infections.

  • First-in-human clinical trials for Influenza A are planned in collaboration with the clinical CRO INFECTA and CHDR in the Netherlands.

Ocular Delivery

Ocular Administration

Ocular GPS543 — eye dropper administering antiviral treatment for viral eye infections

Viral Eye Infections

  • Viral eye infections are highly contagious and can cause irreversible vision loss.

  • Adenovirus is the main cause, and no effective antivirals are currently available.

  • ViroCarb candidates show strong anti-adenoviral activity and are expected to work broadly against other viral infections of the eye.*

Market Insights

*No approved treatment exists for up to 90% of viral eye infections (adenovirus). The market for treatable viral infections is projected to reach up to $8.2B by 2030.

Sources: HSV1&HSV2 (Grand View Research·2024); CMV (Mordor Intelligence·2026); Varicella (Data Bridge Market Research, 2022)

Interested in the pipeline details?

Request our full pipeline data package including preclinical data summaries.

Request Pipeline Data